ORPHA:398097
Neonatal antiphospholipid syndrome
Also known as: Neonatal Hughes syndrome · Neonatal antiphospholipid antibody syndrome
Publications
126
61.7th percentile
Trials
0
Interventional, condition-specific
Researchers
608
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
antiphospholipid syndrome is a rare, secondary, autoimmune disease characterized by single or recurrent episodes of venous, arterial or mixed thrombosis in a neonate whose mother does not have antiphospholipid syndrome manifestations. Patients present positive antiphospholipid antibodies and may have additional abnormalities associated (e.g. cardiac valve disease, livedo reticularis, thrombocytopenia, nephropathy, neurological manifestations).
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018357
- UMLS:C4751518
Additional Mondo synonyms (2)
neonatal Hughes syndrome · neonatal antiphospholipid antibody syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
126 matched papers (76 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 62 for broader category antiphospholipid syndrome
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
126
126 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
126 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
76 in the last 10 years · high confidence · 61.7th percentile (publications denominator)
Phrase hits: 126 · MeSH hits: 0
Who's working on it?
608
Distinct author names in 126 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Wang X10 papers · 2026
Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China. wxt65@sdfmu.edu.cn.
Papers in Europe PMC - 02Cai Y5 papers · 2026
Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
Papers in Europe PMC - 03Gao R5 papers · 2026
( 610041) The Reproductive Medical Center, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu 610041, China.
Papers in Europe PMC - 04Lv Q5 papers · 2026
Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
Papers in Europe PMC - 05Qin L5 papers · 2026
( 610041) The Reproductive Medical Center, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu 610041, China.
Papers in Europe PMC - 06Yachha SK5 papers · 1999
Department of Gastroenterology (Pediatric GE), Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow.
Papers in Europe PMC - 07Cui L4 papers · 2024
Department of Laboratory Medicine, Peking University Third Hospital, Beijing 100191, China.
Papers in Europe PMC - 08De Carolis S4 papers · 2023
Dipartimento di Ginecologia e Ostetricia, Università Cattolica del Sacro Cuore, Rome, Italy.
Papers in Europe PMC - 09Huo R4 papers · 2026
Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
Papers in Europe PMC - 10Qi W4 papers · 2026
Department of Obstetrics and Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 62 trials are registered for antiphospholipid syndrome, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
62 interventional trials matched antiphospholipid syndrome, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: antiphospholipid syndrome
62
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06504420·NOT YET RECRUITING·The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study
Conditions: Primary Antiphospholipid Syndrome·Matched via name phrase
- NCT06379646·RECRUITING·An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Conditions: Systemic Lupus Erythematosus · Systemic Sclerosis · Inflammatory Myopathy · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis·Matched via name phrase
- NCT05983952·RECRUITING·Anti-CD38 Antibody Treating APS With Thrombocytopenia
Conditions: Antiphospholipid Syndrome · Thrombocytopenia·Matched via name phrase
- NCT05859997·ENROLLING BY INVITATION·Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus (SLE) · Sjogren's Syndrome · Systemic Sclerosis · Inflammatory Myopathy·Matched via name phrase
- NCT06614270·RECRUITING·Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
Conditions: Systemic Sclerosis (SSc) · ANCA Associated Vasculitis (AAV) · Idiopathic Inflammatory Myopathy (IIM) · Sjogren's Syndrome·Matched via name phrase
- NCT06978647·RECRUITING·A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus (SLE) · Systemic Sclerosis (SSc) · Inflammatory Myopathy · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis·Matched via name phrase
- NCT06747312·RECRUITING·Effect of Belimumab on Antibody Titers in Primary APS Patients
Conditions: Antiphospholipid Syndrome (APS)·Matched via name phrase
- NCT07212322·NOT YET RECRUITING·A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus · Idiopahic Inflammatory Myopathies · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Sjögren's Syndrome·Matched via name phrase
- NCT05671757·RECRUITING·Daratumumab in Primary Antiphospholipid Syndrome
Conditions: Autoimmune Disorders·Matched via name phrase
- NCT07301164·NOT YET RECRUITING·Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
Conditions: System Lupus Erythematosus · Systemic Sclerosis (SSc) · Inflammatory Myositis · Antiphospholipid Syndrome·Matched via name phrase
- NCT06371417·RECRUITING·Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Conditions: Antiphospholipid Syndrome (APS) · Bullous Pemphigoid (BP) · Behçet's Syndrome (BS) · Dermatomyositis (DM)·Matched via name phrase
- NCT07236762·RECRUITING·An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus · Lupus Nephritis (LN) · Sjogren's Syndrome · Inflammatory Myopathy·Matched via name phrase
- NCT07123519·RECRUITING·A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus (SLE) · Lupus Nephritis (LN) · Sjogren's Syndrome (SS) · Inflammatory Myopathy·Matched via name phrase
- NCT07236801·RECRUITING·Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus (SLE) · Systemic Sclerosis · Sjogren's Syndrome (SS) · Inflammatory Myopathy·Matched via name phrase
- NCT05995600·RECRUITING·Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
Conditions: Antiphospholipid Syndrome · Ischemic Stroke · Transient Ischemic Attack · Cerebrovascular Disease·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Neonatal antiphospholipid syndrome" OR "Neonatal Hughes syndrome" OR "Neonatal antiphospholipid antibody syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Neonatal antiphospholipid syndrome" OR "Neonatal Hughes syndrome" OR "Neonatal antiphospholipid antibody syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"antiphospholipid syndrome"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:18:03.214Z
